Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-03-23
2003-11-11
Krass, Frederick (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S822000, C514S925000, C514S954000, C514S947000, C514S506000, C514S512000, C514S678000, C514S715000, C514S717000, C514S724000, C514S730000, C424S407000, C424S427000, C424S428000
Reexamination Certificate
active
06645978
ABSTRACT:
BACKGROUND OF THE INVENTION
Dry eye, also known generically as keratoconjunctivitis sicca, is a common ophthalmological disorder affecting millions of Americans each year. The condition is particularly widespread among post-menopausal women due to hormonal changes following the cessation of fertility. Dry eye may afflict an individual with varying severity. In mild cases, a patient may experience burning, a feeling of dryness, and persistent irritation such as is often caused by small bodies lodging between the eye lid and the eye surface. In severe cases, vision may be substantially impaired. Other diseases, such as Sjogren's disease and cicatricialpemphigoid may also manifest dry eye complications.
Dry eye consists of a variety of conditions of diverse origin which affect the tear film and the ocular surface. Dry eye is a disorder of the precorneal tear film due to tear deficiency or excessive tear evaporation which causes damage to the interpalpebral ocular surface and is associated with symptoms of ocular discomfort. Symptoms which include burning, stinging and photophobia are associated with clinical signs of interpalpebral surface damage and tear instability hyperosmolarity. Dry eye is a consequence of a variety of pathogenic causes and afflicts individuals with a broad range of severity. However, a common denominator in dry eye patients is the breakdown of the ocular tear film resulting in dehydration and damage to the exposed ocular surface.
Dry eye occurs in patients with Sjogren's syndrome, an autoimmune disease which destroys the lacrimal gland and reduces tear production. Approximately 75% of people over the age of 65 suffer from dry eye as tear production decreases with the normal aging process. Hormonal changes occurring during pregnancy, lactation, oral contraceptive use, menstruation and menopause can cause dry eye. Dry eye can occur when ocular surface changes occur in rheumatoid arthritis, diabetes, thyroid abnormalities, asthma, cataracts, glaucoma and lupus. Medications which induce dry eye by decreasing tear production include antidepressants, decongestants, antihistamines, antihypertensives, oral contraceptives, diuretics and anti-ulcer agents. Dry eye can result from exposure to smoke, fluorescent lights, air pollution, wind, heaters, air conditioning. Lack of blinking during computer use can elicit signs and symptoms of dry eye. The condition can result from living in a dry climate or exposure to dry conditions such as in airline travel. Dry eye can result from unusual facial anatomy which affects blinking, or irregularities of the cornea which result in uneven tear distribution. Decreased tear lipid production occurs in infection or inflammation of the meibomian glands, resulting in excessive tear evaporation. Decreased corneal sensitivity can also lead to insufficient reflex tearing and decreased blinking. This can occur as a result of trauma to the eye, for example nerve damage due to flap formation in LASIK surgical procedures or from the corneal photoablation effected by such procedures, or in severe keratitis or excessive contact lens wear.
Although it appears that dry eye may result from a number of unrelated pathogenic causes, all presentations of the complication share a common effect, that is the breakdown of the pre-ocular tear film, which results in dehydration of the exposed outer surface of the eye and many of the symptoms outlined above (Lemp, Report of the National Eye Institute/Industry Workshop on Clinical Trials in Dry Eyes,
The CLAO Journal
, volume 21, number 4, pages 221-231 (1995)).
Practitioners have taken several approaches to the treatment of dry eye. One common approach has been to supplement and stabilize the ocular tear film using so-called artificial tears instilled throughout the day. Other approaches include the use of ocular inserts that provide a tear substitute or stimulation of endogenous tear production.
Examples of the tear substitution approach include the use of buffered, isotonic saline solutions, aqueous solutions containing water soluble polymers that render the solutions more viscous and thus less easily shed by the eye. Tear reconstitution is also attempted by providing one or more components of the tear film such as phospholipids and oils. Phospholipid compositions have been shown to be useful in treating dry eye; see, e.g., McCulley and Shine, Tear film structure and dry eye,
Contactologia
, volume 20(4), pages 145-49 (1998); and Shine and McCulley, Keratoconjunctivitis sicca associated with meibomian secretion polar lipid abnormality,
Archives of Ophthalmology
, volume 116(7), pages 849-52 (1998). Examples of phospholipid compositions for the treatment of dry eye are disclosed in U.S. Pat. No. 4,131,651 (Shah et al.), U.S. Pat. No. 4,370,325 (Packman), U.S. Pat. No. 4,409,205 (Shively), U.S. Pat. Nos. 4,744,980 and 4,883,658 (Holly), U.S. Pat. No. 4,914,088 (Glonek), U.S. Pat. No. 5,075,104 (Gressel et al.), U.S. Pat. No. 5,278,151 (Korb et al.), U.S. Pat. No. 5,294,607 (Glonek et al.), U.S. Pat. No. 5,371,108 (Korb et al.), and U.S. Pat. No. 5,578,586 (Glonek et al.). U.S. Pat. No. 5,174,988 (Mautone et al.) discloses phospholipid drug delivery systems involving phospholipids, propellants and an active substance.
U.S. Pat. No. 3,991,759 (Urquhart) discloses the use of ocular inserts in the treatment of dry eye. Other semi-solid therapy has included the administration of carrageenans (U.S. Pat. No. 5,403,841, (Lang)) which gel upon contact with naturally occurring tear film.
Another approach involves the provision of lubricating substances in lieu of artificial tears. For example, U.S. Pat. No. 4,818,537 (Guo) discloses the use of a lubricating, liposome-based composition, and U.S. Pat. No. 5,800,807 (Hu et al.) discloses compositions containing glycerin and propylene glycol for treating dry eye.
Aside from the above efforts, which are directed primarily to the alleviation of symptoms associated with dry eye, methods and compositions directed to treatment of the underlying dry eye condition have also been pursued. For example, U.S. Pat. No. 5,041,434 (Lubkin) discloses the use of sex steroids, such as conjugated estrogens, to treat dry eye condition in post-menopausal women; U.S. Pat. No. 5,290,572 (MacKeen) discloses the use of finely divided calcium ion compositions to stimulate pre-ocular tear film production; and U.S. Pat. No. 4,966,773 (Gressel et al.) discloses the use of microfine particles of one or more retinoids for ocular tissue normalization.
Although these approaches have met with some success, problems in the treatment of dry eye nevertheless remain. The use of tear substitutes, while temporarily effective, generally requires repeated application over the course of a patient's waking hours. It is not uncommon for a patient to have to apply artificial tear solution ten to twenty times over the course of the day. Such an undertaking is not only disruptive and time consuming, but is also potentially very expensive.
The use of ocular inserts is also problematic. Aside from cost, they are often unwieldy and uncomfortable. Further, as foreign bodies introduced in the eye, they can be a source of contamination leading to infections. In situations where the insert does not itself produce and deliver a tear film, artificial tears must still be instilled on a regular and frequent basis.
Mucins are proteins which are heavily glycosylated with glucosamine-based moieties. Mucins provide protective and lubricating effects to epithelial cells, especially those of mucosal membranes. Mucins have been shown to be secreted by vesicles and discharged on the surface of the conjunctival epithelium of human eyes (Greiner et al., Mucus Secretory Vesicles in Conjunctival Epithelial Cells of Wearers of Contact Lenses,
Archives of Ophthalmology
, volume 98, pages 1843-1846 (1980); and Dilly et al., Surface Changes in the Anaesthetic Conjunctiva in Man, with Special Reference to the Production of Mucus from a Non-Goblet-Cell Source,
British Journal of Ophthalmology
, volume 65, pages 833-842 (1981))
Gamache Daniel A.
Graff Gustav
Hellberg Mark R.
Klimko Peter G.
Yanni John M.
Alcon Inc.
Copeland Barry L.
Krass Frederick
Ostrup Clinton
LandOfFree
Lipoxin A4 and its analogs for the treatment of dry eye does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lipoxin A4 and its analogs for the treatment of dry eye, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lipoxin A4 and its analogs for the treatment of dry eye will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3156765